<DOC>
	<DOCNO>NCT02945228</DOCNO>
	<brief_summary>The main objective study evaluate safety effectiveness paritaprevir/ritonavir/ombitasvir ribavirin use participant infect chronic hepatitis C virus ( HCV ) genotype 2 daily practice Japan .</brief_summary>
	<brief_title>Drug Use-Results Survey Participants Infected With Hepatitis C Virus Genotype 2</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>HCV genotype 2 participant treat paritaprevir/ritonavir/ombitasvir plus ribavirin daily practice . Participants previously treat paritaprevir/ritonavir/ombitasvir ribavirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Paritaprevir</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Hepatitis C Virus ( HCV )</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Ritonavir</keyword>
</DOC>